Skip to main content

Recordati-Industria Chimica Value Stock - Dividend - Research Selection

Recordati-Industria Chimica e Farmaceutica S.p.A.

ISIN: IT0003828271, WKN: A0EABR

Market price date: 28.05.2021
Market price: 44,65 EUR




Recordati-Industria Chimica e Farmaceutica S.p.A. Fundamental data and company key figures of the share

Annual reports in EUR
Key figures 04-04-2021
Cash flow
Net operating cash flow 403.575.000
Capital Expenditures -131.678.000
Free cash flow 271.896.992
Balance sheet
Total Equity 1.275.980.000
Liabilities & Shareholders equity 2.711.650.000
Income statement
Net income 354.984.000
Eps (diluted) 1,700
Diluted shares outstanding 206.296.000
Net sales/revenue 1.448.870.000

Fundamental ratios calculated on: 28-05-2021

Ratios
Key figures 28-05-2021
Cash flow
P/C 22,82
   
P/FC 33,88
Balance sheet
ROI13,09
ROE47,06
Income statement
P/E26,27
Div. Yield2,35%
P/B7,22
P/S6,36


Do you want to do make a detailed fundamental analysis of this stock?

✓ NEW Fundamental API Access to 500 data points per month
Fundamental data up to 25 years
Comparison to all other stocks by the FScore
Time saving!

How our site works ...

Non-binding 7 days without automatic subscription
 No termination required after the free week
Finanzoo fundamental analysis
Data updated daily
Virtual depots
Share alarms via email
Subscription can be canceled at any time at the end of the month 
Choice of desired shares
Over 2000 stock analyzes available
Bitcoin payment possible if you do not want to subscribe

Price for monthly subscription $ 19.99 / month including VAT.



DescriptionData
SymbolRER1.F
Market Capitalization11.171.760.128,00 USD
Country
IndicesNO INDEX
Sectors
Raw Data SourceIFRS in Millionen EUR
Stock Split
Internetwww.recordati.com


Description of the company

Recordati Industria Chimica e Farmaceutica SpA is an Italy-based group engaged in the research, development, manufacture and marketing of pharmaceuticals. It promotes a wide range of pharmaceuticals, both proprietary and under license, in a number of therapeutic areas, such as Antibiotics and Antiviral, Cardiovascular, Central nervous system, Dermatological, Gastroenterology, Genital-urinary system, Muscular-skeletal disorders and pain therapy, Obstetrics and Gynecology and over the counter (OTC) pharmaceuticals. The Company is engaged in the research and development of new drug entities within the cardiovascular and urogenital therapeutic areas and of treatments for rare diseases. It’s product is ZANIDIP, a latest generation calcium-channel blocker for the treatment hypertension. It operates through Italchimici SpA and Pro Farma AG.

The Finanzoo GmbH assumes no liability for the accuracy of the information! All information is provided without warranty. Sources:: www.bundesanzeiger.de, www.sec.gov, www.recordati.com